Action Biogen - IDP

Biogen Inc (IDP) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

189,32

( 0,12% )

Prix Achat

187,74

Prix Vente

189,60

Volume échangé

111

188,82 Fourchette du Jour 189,32

103,55 Plage de 52 semaines 192,50

Clôture Veille

189,10

Ouverture

188,86

Dernière Transaction

189.32

Dernière heure de transaction

10:02:34

Volume moyen (3 m)

450

Volume financier

VWAP

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen Diranersen presentation...

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. Acquisition adds multiple immunology assets to Biogen’s portfolio...

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy Designation is supported by an exploratory analysis...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus Steroid use...

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients...

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region With this transaction, Biogen now owns exclusive...

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating...

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy The approval was anchored on data from the pivotal DEVOTE...

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual...

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	12.5	7.06933604796	176.82	192.5	175.68	672	189.3251563	DE
4	21.86	13.0538636092	167.46	192.5	166.08	472	179.23962181	DE
12	38.56	25.5770761475	150.76	192.5	147.04	450	168.49030525	DE
26	40.92	27.5741239892	148.4	192.5	135.85	607	160.47582596	DE
52	75.62	66.508355321	113.7	192.5	103.55	1032	138.388447	DE
156	-74.48	-28.233510235	263.8	270.6	98.78	764	154.32764385	DE
260	-106.93	-36.0945147679	296.25	317.45	98.78	800	191.94050559	DE

IDP - Frequently Asked Questions (FAQ)

What is the current Biogen Inc share price?

The current share price of Biogen Inc is 189,32 €

What is the 1 year trading range for Biogen Inc share price?

Biogen Inc has traded in the range of 103,55 € to 192,50 € during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biogen Inc (IDP)

Biogen Inc (IDP) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

IDP Dernières nouvelles

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

IDP - Frequently Asked Questions (FAQ)

IDP Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biogen Inc (IDP)

Biogen Inc (IDP) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

IDP Dernières nouvelles

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

IDP - Frequently Asked Questions (FAQ)

IDP Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités